Skip to main content
. 2009 Aug 1;80(4):472–477. doi: 10.3109/17453670903110642

Figure 1.

Figure 1.

Cox-adjusted cumulative survival of TEAs for rheumatoid arthritis in one hospital specialized in the treatment of rheumatoid arthritis (n = 776) and in 19 other hospitals (n = 681) in Finland from 1982 through 2006. The endpoint was defined as revision for any reason. Adjustment was made for age, sex, and prosthesis design.